Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Imfinzi® (durvalumab) – New orphan indication
September 5, 2022 - AstraZeneca announced the FDA approval of Imfinzi (durvalumab), in combination with gemcitabine and cisplatin, for the treatment of adult patients with locally advanced or metastatic biliary tract cancer (BTC).
